撒哈拉以南非洲多种HIV-1亚型感染者中整合酶链转移抑制剂的原发性耐药
该研究对撒哈拉以南非洲五国425例未使用过整合酶链转移抑制剂(INSTI)的HIV感染者进行pol基因测序,主要INSTI耐药突变仅在低于20%的检测阈值下检出,患病率为2.4%,作者认为基于INSTI的方案在该地区不同主要HIV-1亚型中预期有效。
要点
- 主要INSTI耐药突变仅在低于20%阈值下检出,总患病率2.4%。
- 辅助突变在≥20%阈值下患病率为15.1%,以L74I/M(10.4%)最常见。
- 作者认为基于INSTI的方案在该地区不同主要HIV-1亚型中预期有效。
核心结论
- 主要INSTI耐药突变罕见,且仅出现在低水平耐药检测阈值下;作者认为基于INSTI的方案预期在该地区不同主要HIV-1亚型中有效。
研究设计与样本
- 研究采用Illumina下一代测序对来自肯尼亚(21.2%)、尼日利亚(7.3%)、南非(22.8%)、乌干达(25.2%)和赞比亚(23.5%)的425例未使用过INSTI的HIV感染成人进行pol基因测序。
- 耐药判读基于IAS 2017突变列表以及Stanford HIVdb中至少对1种INSTI耐药罚分≥10的辅助突变。
- 耐药进一步按敏感度阈值分类:≥20%(Sanger测序)和1%-20%为低频变异(下一代测序)。
主要发现
- 425例基因型中,48.7%为C亚型,28.5%为A亚型,10.1%为D亚型,2.8%为G亚型,9.9%为重组型。
- 主要INSTI耐药突变仅在<20%阈值下检出,患病率为2.4%(A亚型2.5%、C亚型2.4%、D亚型0%、G亚型8.3%、重组型2.4%),包括T66A/I(0.7%)、E92G(0.5%)、Y143C/S(0.7%)、S147G(0.2%)和Q148R(0.5%)。
- 辅助突变在≥20%阈值下患病率为15.1%(A亚型23.1%、C亚型8.7%、D亚型11.6%、G亚型25%、重组型23.8%),包括L74I/M(10.4%)、Q95K(0.5%)、T97A(4%)、E157Q(0.7%)和G163R/K(0.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the prevalence and patterns of major and accessory resistance mutations associated with integrase strand transfer inhibitors (INSTIs), across diverse HIV-1 subtypes in sub-Saharan Africa. METHODS: pol gene sequences were obtained using Illumina next-generation sequencing from 425 INSTI-naive HIV-infected adults from Kenya (21.2%), Nigeria (7.3%), South Africa (22.8%), Uganda (25.2%) and Zambia (23.5%). Drug resistance interpretation was based on the IAS 2017 mutation list and accessory mutations from Stanford HIVdb with resistance penalty scores of ≥10 to at least 1 INSTI. Resistance was further classified based on sensitivity thresholds of ≥20% (Sanger sequencing) and 1%-20% for low-frequency variants (next-generation sequencing). RESULTS: Of 425 genotypes, 48.7% were subtype C, 28.5% A, 10.1% D, 2.8% G and 9.9% were recombinants. Major INSTI resistance mutations were detected only at <20% threshold, at a prevalence of 2.4% (2.5% in subtype A, 2.4% C, 0% D, 8.3% G and 2.4% in recombinants) and included T66A/I (0.7%), E92G (0.5%), Y143C/S (0.7%), S147G (0.2%) and Q148R (0.5%). Accessory mutations occurred at a prevalence of 15.1% at the ≥20% threshold (23.1% in subtype A, 8.7% C, 11.6% D, 25% G and 23.8% in recombinants), and included L74I/M (10.4%), Q95K (0.5%), T97A (4%), E157Q (0.7%) and G163R/K (0.7%). CONCLUSIONS: Major INSTI resistance mutations were rare and only occurred at low-level resistance detection thresholds. INSTI-based regimens are expected to be effective across the different major HIV-1 subtypes in the region.
引用
- Inzaule SC, Hamers RL, Noguera-Julian M, et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J Antimicrob Chemother. 2018. PMID: 29462322. doi:10.1093/jac/dky005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。